Company intelligence / Profile preview
ResVita Bio
Berkeley, California, United Statesresvitabio.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
ResVita Bio has received NIH grants to develop treatments for Netherton Syndrome and severe atopic dermatitis. The company has received Rare Pediatric Disease Designation for Netherton Syndrome from the FDA and is preparing to enter clinical trials in 2025.
- Therapeutic areas
- Dermatology
- Modalities
- Genetically engineered bacteriaTopical cell therapyProtein therapy
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Beyond the preview
Go deeper on ResVita Bio.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ResVita Bio.